Pozen, Sanofi end deal for omeprazole/aspirin combo

Sanofi (Euronext:SAN; NYSE:SNY) returned to Pozen Inc. (NASDAQ:POZN) U.S. rights to omeprazole/ aspirin combinations PA32540 and PA8140 as the parties terminated a September 2013 deal.

"The regulatory timeline has taken longer than any of us expected," said Pozen President and CEO John Plachetka on a conference call. ...